Leonard L. Mazur - Jan 11, 2022 Form 3 Insider Report for Hillstream BioPharma Inc. (HILS)

Role
Director
Signature
/s/ Randy Milby as Attorney-In-Fact for Leonard Mazur
Stock symbol
HILS
Transactions as of
Jan 11, 2022
Transactions value $
$0
Form type
3
Date filed
1/11/2022, 08:41 PM
Previous filing
Oct 13, 2021
Next filing
Jan 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HILS Convertible Note Jan 11, 2022 Common stock Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 22, 2020, the Registrant issued the Reporting Person a $300,000 note which matures on the earlier of (i) December 31, 2023 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney